MEDIPOSTCO.,LTD.

078160KOSDAQPharmaceuticals

MEDIPOSTCO.,LTD. (078160, KOSDAQ) reported KRW 74bn revenue in 2025.

Reported financials

Figures are as filed with the Korean regulator, in billions of won (KRW bn). We do not convert to dollars — an exchange rate would be a number we made up, not one the company reported.

YearRevenueOperating profitNet profitAssetsEquityBasis
202369-255449314Consolidated
202471-49-63414253Consolidated
202574-68-86432250Consolidated

Ratios, year by year

Each ratio is computed inside its own year. A dash means the input was missing or the denominator was zero — not that the value is zero.

YearOperating marginNet marginEquity / assetsReturn on equity
2023-36.6%7.2%69.8%1.6%
2024-68.7%-89.7%61%-25.1%
2025-92.3%-116.7%57.9%-34.4%

Revenue moved 7.3% between 2023 and 2025.

These are arithmetic, not judgements. We do not say whether a margin is good or bad, and we do not rank companies against each other.

Market size

Market capitalisationKRW 349bn
Close priceKRW 8,900
Listed shares39,204,603
Price as of20260909

Market capitalisation is what buyers are betting the company is worth. It is not something the company produced, so we never present it as output or productivity.

Workforce — a side measure, not the main one

Employees (2025)342
Women197 (57.6%)
Average tenure5.4 years
Annual pay, menKRW 68,000,000
Annual pay, womenKRW 57,000,000
Pay ratio, women to men83.8%

Other companies in Pharmaceuticals

181 listed companies file under this classification. Showing 12.

See the whole Pharmaceuticals list →